Reports

EchoStar generated 3796014000 in revenue in Q4 2025 and reported a net loss attributable to EchoStar of 1207183000, primarily due to 1150543000 in impairments and other charges. Adjusted OIBDA improved year-over-year despite subscriber declines in Pay-TV and Broadband.

• Total Q4 revenue was 3796014000 compared to 3966938000 in Q4 2024.
• Net loss attributable to EchoStar was 1207183000.

MongoDB delivered a strong fourth quarter with 27% revenue growth and achieved a 'Rule of 40' performance, demonstrating durable growth alongside significant operating margin expansion. The company saw broad-based demand for its platform, particularly in AI-related workloads and Atlas adoption.

• Total revenue grew 27% year-over-year to $695.1 million, driven by strong subscription growth.
• Atlas revenue increased 29% year-over-year, now representing approximately 72% of total revenue.

For Q4 2025, Venture Global generated revenue of 4445000000 and net income attributable to common stockholders of 1067000000, driven by higher LNG sales volumes from the Plaquemines Project commissioning, partially offset by lower LNG sales prices and higher interest expense.

• Revenue increased 192% year-over-year to 4445000000.
• Income from operations rose to 1718000000, up 189% year-over-year.

Credo delivered a record-breaking third quarter with revenue exceeding $400 million, representing over 200% year-over-year growth. The company saw significant expansion in its AI infrastructure solutions, particularly in AECs and ICs, while maintaining strong gross margins and achieving substantial profitability on both a GAAP and non-GAAP basis.

• Revenue grew 201.5% year-over-year to $407.0 million, driven by AI infrastructure demand.
• Non-GAAP net income reached $208.8 million, or $1.07 per diluted share.

AST SpaceMobile generated significant Q4 revenue growth year-over-year, primarily from product and service revenues tied to gateway deliveries and government contracts. However, the company continued to report substantial net losses as operating expenses and infrastructure investments remained elevated.

• Q4 revenue increased significantly year-over-year to $54.305 million.
• Net loss attributable to common stockholders was $73.966 million.

Norwegian Cruise Line Holdings reported a solid fourth quarter with revenue growth of 6% and Adjusted EBITDA exceeding guidance, despite a significant drop in GAAP net income due to non-cash charges. The company is undergoing a leadership transition with new CEO John W. Chidsey focusing on improving execution and financial discipline to address recent commercial strategy misalignments.

• Q4 Adjusted EPS of $0.28 exceeded guidance of $0.27, representing a 46% increase year-over-year.
• Occupancy reached 101.8% in the fourth quarter, a 100 basis point improvement compared to the prior year.

Aaon delivered strong Q4 2025 results with net sales increasing 42.5% year-over-year, driven by robust demand for data center equipment under the BASX brand. While gross margins were slightly pressured by capacity expansion costs in Memphis, the company achieved a record total backlog of $1.83 billion, positioning it for continued growth in 2026.

• Net sales grew 42.5% to $424.2 million in Q4 2025 compared to $297.7 million in Q4 2024.
• Total backlog reached a record $1.83 billion, up 110.9% year-over-year, driven by a 141.3% increase in BASX-branded products.

ADT generated Q4 2025 revenue of 1276000000, up 1% year-over-year, with operating income of 333000000. GAAP income from continuing operations was 146000000, or 0.17 per diluted share, while adjusted EPS increased to 0.23. Operating cash flow totaled 374000000 in the quarter.

• Total revenue increased 1% year-over-year to 1276000000.
• Operating income rose 9% to 333000000.

Belite Bio reported a GAAP net loss of 25324000 for Q4 2025, driven by higher R&D and G&A expenses associated with clinical trials and share-based compensation, while strengthening its balance sheet with significant cash and investments following a public offering.

• GAAP net loss was 25324000 compared to 10100000 in Q4 2024.
• R&D expenses increased to 14624000 from 7254000 year-over-year.

Sealed Air generated $1.401 billion in Q4 2025 revenue, up 2.1% year-over-year, with net earnings of $44.4 million compared to a slight loss in the prior year period. Adjusted EBITDA improved to $278.0 million, supported by productivity benefits and lower operating costs.

• Net sales increased 2.1% year-over-year to $1.401 billion.
• Net earnings improved to $44.4 million from a loss in Q4 2024.

Riot generated Q4 2025 revenue of 131700000 driven primarily by bitcoin mining operations. Production declined sequentially due to higher network difficulty and the April halving impact, while cost to mine increased. The company exited the quarter with record hash rate capacity and strong liquidity.

• Total revenue was 131700000 in Q4 2025.
• Bitcoin production totaled 1324 BTC in the quarter.

RadNet generated record quarterly revenue of 547712000 and operating income of 27825000 in Q4 2025, driven by double-digit growth in advanced imaging volumes and strong Digital Health expansion. Despite higher expenses and tax adjustments, adjusted earnings remained solid.

• Total revenue increased 14.8% year-over-year to 547712000.
• Operating income rose to 27825000 from 24525000 in the prior year.

Core Scientific reported a significant shift in its business model during Q4 2025, with colocation revenue growing nearly 268% year-over-year as the company pivots toward high-density colocation and AI workloads. While total revenue declined due to lower bitcoin mining output, the company achieved a net income of $216 million, largely driven by non-cash fair value gains on warrant liabilities.

• Colocation revenue surged to $31.3 million from $8.5 million in the prior year, reflecting the strategic expansion into high-density computing.
• Net income reached $216.0 million, a major turnaround from a $291.1 million loss last year, primarily due to a $330.3 million non-cash fair value gain.

CRC generated total operating revenues of 924000000 and net income of 12000000 in Q4 2025. The company produced 137000 barrels of oil equivalent per day, generated 115000000 of free cash flow and maintained strong liquidity with 132000000 in cash and cash equivalents at quarter end.

• Average net production was 137000 BOE per day, with 109000 barrels per day of oil.
• Net income totaled 12000000 and diluted EPS was 0.14.

Ingram Micro delivered a strong fourth quarter, exceeding the high end of its net sales and EPS guidance. The company achieved 11.5% year-over-year revenue growth and generated its highest quarterly adjusted free cash flow in over a decade, driven by strength in AI-enablement projects and the Xvantage platform.

• Net sales of $14.9 billion grew 11.5% year-over-year, surpassing the high end of the guidance range.
• Adjusted free cash flow reached $1.63 billion, the highest quarterly level in more than 10 years.

In Q4 2025, Archer generated 300000 in revenue, reported a net loss of 188900000, and increased operating expenses as it continued investing in certification, production and commercialization efforts, while maintaining strong liquidity.

• Revenue was 300000 in Q4 2025.
• Total operating expenses rose to 234700000 in Q4 2025.

StoneCo delivered a solid fourth quarter with a 13% year-over-year increase in total revenue and a 12.4% increase in adjusted net income from continuing operations. The company successfully executed its simplification strategy, including the divestment of Linx software assets, while expanding its MSMB active client base to 4.7 million and more than doubling its credit portfolio.

• Adjusted Basic EPS grew 26.8% year-over-year to R$2.87, outpacing net income growth due to R$3.0 billion in share buybacks.
• The credit portfolio reached R$2.8 billion, a 134.9% increase year-over-year, with a focus on working capital solutions for MSMBs.

For the quarter ended December 31, 2025, Apogee reported a net loss of 255843000 and an operating loss of 285595000, driven by research and development expenses of 214712000 and general and administrative expenses of 70883000. The company ended the year with 131549000 in cash and cash equivalents.

• Net loss for Q4 2025 was 255843000.
• Operating loss totaled 285595000 for the quarter.

Pampa Energia delivered a strong Q4 2025 performance with a 16% revenue increase and a 52% rise in net income. Growth was primarily driven by accelerated shale oil production at Rincón de Aranda and a new regulatory framework in the power generation segment, which improved spot remuneration for thermal units.

• Net income attributable to shareholders rose 52% year-on-year to $161 million.
• Adjusted EBITDA increased 26% to $230 million, driven by oil production and power generation margins.

Life360 delivered 26% year-over-year revenue growth in Q4 2025, driven by subscription and other revenue strength. Adjusted EBITDA margin reached a record 22%, while net income was elevated due to a one-time, non-cash income tax benefit.

• Total revenue increased 26% year-over-year to 145979000.
• Adjusted EBITDA reached 32433000 with a 22% margin.

Tidewater delivered strong fourth quarter results driven by higher average vessel day rates and improved utilization. Revenue and net income increased year-over-year, reflecting continued strength in offshore activity and operating leverage across the fleet.

• Q4 revenue increased to 302300000.
• Net income reached 44200000 for the quarter.

In Q4 2025, Plug Power delivered revenue growth of 17.6% year-over-year to $225.20M and achieved a positive gross profit, but reported a substantial net loss driven primarily by non-cash impairment and related charges.

• Revenue increased 17.6% year-over-year to 225200000 in Q4 2025.
• Gross profit was positive at 5500000, representing 2.4% of sales.

Alamo Group reported a mixed fourth quarter with a 3% decline in net sales and a significant drop in net income. While the Industrial Equipment Division performed strongly with record margins, the Vegetation Management Division faced severe headwinds from weak end-market demand in agriculture and tree care, leading to a contraction in overall profitability.

• Industrial Equipment Division achieved 4.2% sales growth and record adjusted EBITDA margins of 17.7%.
• Vegetation Management Division sales fell 13.2% due to low housing demand, low crop prices, and elevated interest rates.

Turning Point Brands saw a 29.2% increase in net sales for Q4 2025, driven by the explosive growth of its Modern Oral products within the Stoker's segment. While the Zig-Zag segment faced headwinds from the Clipper business wind-down, the company achieved strong adjusted EBITDA growth and maintained a robust liquidity position.

• Modern Oral net sales surged 266% to $41.3 million, now representing 34% of total company sales.
• Stoker's segment net sales grew 69.5% to $81.0 million, fueled by triple-digit Modern Oral growth.

Helios delivered solid fourth quarter results with double-digit revenue growth across both Hydraulics and Electronics segments. Gross and operating margins expanded significantly, driving strong EPS growth and improved leverage.

• Q4 net sales increased 17% year-over-year to 210700000.
• Gross margin expanded 350 basis points to 33.6%.

Asana delivered a strong fourth quarter with revenue growing 9% year-over-year to $205.6 million, while significantly improving profitability. The company achieved a non-GAAP operating margin of 9% and saw substantial growth in adjusted free cash flow, driven by efficiency gains and strong retention among large enterprise customers.

• Q4 revenue reached $205.6 million, representing a 9% year-over-year increase.
• Non-GAAP operating margin expanded by 10 percentage points year-over-year to reach 9%.

For Q4 2025, Dyne reported a net loss of 111955000, driven by research and development expenses of 95431000 and general and administrative expenses of 20698000. The company ended the year with 1110562000 in cash, cash equivalents and marketable securities, supporting runway into Q1 2028.

• Net loss for Q4 2025 was 111955000 compared to 89540000 in Q4 2024.
• Research and development expenses increased to 95431000.

Dave delivered a strong Q4 2025, with revenue increasing 62% year-over-year to $163.7 million and net income growing 292% to $66.0 million. The company saw significant improvements in unit economics, driven by its CashAI underwriting engine, which helped reduce delinquency rates while originations grew 50%. Dave also expanded its share repurchase authorization to $300 million.

• Q4 revenue grew 62% year-over-year to $163.7 million, marking the third consecutive quarter of 60%+ growth.
• Net income reached $66.0 million, a 292% increase compared to the prior year period.

Surgery Partners reported a 2.4% increase in Q4 revenue to $885 million, though results were impacted by significant and unanticipated headwinds leading to a net loss of $15 million. Despite margin pressure and a decrease in total surgical cases, the company saw growth in same-facility metrics and higher-acuity procedures, while initiating a $200 million share repurchase program.

• Revenue grew 2.4% year-over-year to $885.0 million for the fourth quarter.
• Same-facility revenues increased 3.5%, driven by a 2.1% increase in revenue per case and a 1.3% increase in same-facility cases.

BigBear.ai reported a significant revenue decline in Q4 2025 due to lower Army program volumes, but substantially narrowed its net loss compared to the prior year. The company ended the year in its strongest cash position ever following significant capital raises and strategic acquisitions of Ask Sage and CargoSeer.

• Revenue decreased 38% year-over-year to $27.3 million, primarily driven by lower volume on Army programs.
• Net loss improved significantly to $5.8 million from $138.2 million in Q4 2024, aided by a $50.2 million non-cash gain on derivative liabilities.

Harrow achieved record quarterly revenue of $89.1 million, representing a 33% year-over-year increase, driven by strong commercial traction of key products like VEVYE, IHEEZO, and TRIESENCE. While the company reported a GAAP net loss for the full year, the fourth quarter showed positive net income and significant growth in Adjusted EBITDA and operating cash flow.

• Record quarterly revenue of $89.1 million, up 33% compared to the prior-year period.
• Adjusted EBITDA for Q4 2025 reached $24.2 million, reflecting improved operating leverage.

Nuvation Bio saw significant growth in the fourth quarter of 2025, driven by the rapid adoption of IBTROZI with 216 new patient starts. Total revenue reached $41.9 million, bolstered by a $25 million milestone payment from Nippon Kayaku. While the company continues to operate at a net loss, it maintains a strong liquidity position with over $529 million in cash and marketable securities to fund its expanding oncology pipeline.

• Successfully started 216 new patients on IBTROZI in Q4 2025, totaling 432 since the June launch.
• Entered an exclusive licensing agreement with Eisai for taletrectinib in Europe and other global territories in January 2026.

Semrush generated 117659000 in Q4 2025 revenue, up 15% year-over-year, with ARR reaching 471400000. The company reported a net loss of 11098000 but delivered non-GAAP operating income of 15028000 and strong free cash flow of 10951000.

• Revenue increased 15% year-over-year to 117659000.
• ARR reached 471400000, up 15% year-over-year.

Quantum Computing Inc. (QCi) reported a 219% increase in Q4 revenue driven by its new Fab 1 facility. While operating expenses rose significantly due to scaling and M&A, the net loss narrowed substantially to $1.6 million, aided by non-cash derivative gains and interest income. The company ended the year with a massive cash position of $737.9 million following a $750 million private placement.

• Revenue increased 219% year-over-year to $198,000, driven by hardware sales and services from the new Fab 1 facility.
• Net loss improved to $1.6 million ($0.01 per share) from $51.2 million in the prior year, largely due to a $7.0 million derivative gain and $13.6 million in interest income.

For Q4 2025, Uniti generated 917300000 in consolidated revenue and 365600000 in Adjusted EBITDA, while reporting a net loss of 305700000 primarily due to a 142500000 loss on extinguishment of debt. Fiber revenue growth remained strong following the Windstream merger.

• Consolidated revenue was 917300000 for the quarter.
• Adjusted EBITDA reached 365600000, representing approximately 40% margin.

Zymeworks reported a decrease in Q4 revenue compared to the prior year as it transitions clinical activities to partners, while significantly reducing its full-year net loss. The company secured a $250 million royalty-backed note from Royalty Pharma to support its share repurchase program and strategic growth, extending its cash runway beyond 2028.

• Secured a $250.0 million non-recourse royalty-backed note financing from Royalty Pharma to support strategic flexibility and share repurchases.
• Partner Jazz Pharmaceuticals expects to complete the supplemental BLA for Ziihera in first-line GEA in 1Q 2026 with a potential 2H 2026 launch.

For Q4 2025, Sionna reported a net loss of 20440000 driven by research and development expenses of 15168000 and general and administrative expenses of 8444000. The company ended the quarter with 310302000 in cash, cash equivalents and marketable securities.

• Net loss for Q4 2025 was 20440000 compared to 15848000 in Q4 2024.
• Research and development expenses increased to 15168000.

Tyra reported a Q4 2025 net loss of 33834000 driven by 36516000 in total operating expenses, reflecting continued investment in dabogratinib clinical development. Cash, cash equivalents and marketable securities totaled 256003000 at quarter end, providing runway through at least 2027.

• Total operating expenses were 36516000 in Q4 2025.
• Net loss was 33834000, or 0.57 per share.

Biohaven reported a net loss of 145555000 for Q4 2025 as the company advanced key late-stage programs while implementing cost optimization measures. R&D expenses declined year-over-year to 121945000, and cash, cash equivalents and marketable securities totaled 319137000 at quarter end.

• Net loss was 145555000, or 1.21 per share.
• R&D expenses declined to 121945000 from 167473000 year-over-year.

Ameresco delivered record quarterly revenue of $581 million, driven by strong project execution and growth in recurring energy asset and O&M revenue. Despite a decrease in net income compared to the prior year (which included a significant gain from a business sale), the company achieved strong operational results and exceeded its annual guidance for energy assets placed in service.

• Achieved record quarterly revenue of $581.0 million, a 9% increase year-over-year.
• Total project backlog reached over $5 billion, with total revenue visibility exceeding $10 billion.

PSI generated 191223000 in Q4 2025 net sales, up 33% year-over-year, driven by strength in power systems and industrial markets. Net income declined to 16077000 as gross margin compressed to 21.9% due to production ramp inefficiencies and a higher effective tax rate.

• Net sales increased 33% year-over-year to 191223000.
• Gross profit was 41811000 with gross margin of 21.9%, down from 29.9% last year.

Ouster delivered strong Q4 2025 results with 62178000 in revenue, 60% GAAP gross margin, and net income of 3985000, driven by royalty revenue and continued product growth, while Adjusted EBITDA turned positive.

• Revenue increased 107% year over year to 62178000.
• GAAP gross margin expanded to 60% and non-GAAP gross margin reached 62%.

For Q4 2025, NextDecade reported a net loss of 45400000, or -0.18 per share, as it continued advancing construction of Trains 1-5 and progressing development of Trains 6-8 at the Rio Grande LNG facility.

• Net loss for Q4 2025 was 45400000.
• EPS for the quarter was -0.18.

uniQure generated approximately $5570000 in revenue in Q4 2025 and reported a net loss of approximately $32032000 as it continued advancing its gene therapy pipeline, including AMT-130, while ending the year with $622500000 in cash and investment securities.

• Estimated Q4 revenue was approximately $5570000 based on full-year disclosures.
• Quarterly net loss was approximately $32032000.

Xeris Biopharma achieved record quarterly revenue of $85.8 million, driven by a 100% increase in Recorlev sales. The company transitioned to profitability in Q4 with a net income of $11.1 million and significantly improved its Adjusted EBITDA, ending the year as a self-funding entity.

• Record Q4 total revenue of $85.8 million, representing 42.8% year-over-year growth.
• Recorlev net revenue doubled to $45.3 million due to strong patient demand.

Limbach delivered record fourth quarter revenue of 186872000 with strong ODR growth of 51.8% year-over-year. Net income increased to 12300000 and adjusted EBITDA rose 30.8% to 27217000, despite gross margin compression related to acquisitions.

• Total revenue increased 30.1% year-over-year to 186872000.
• ODR revenue grew 51.8% to 144967000, representing 77.6% of total revenue.

Astrana Health delivered a strong fourth quarter with revenue growing 43% year-over-year to $950.5 million, driven by significant expansion in its Care Partners segment. Despite a material weakness in internal controls related to acquisition accounting, the company achieved record annual results and provided optimistic 2026 guidance reflecting continued growth from the Prospect Health integration.

• Quarterly revenue increased 43% to $950.5 million, primarily driven by a 38% increase in Care Partners revenue.
• Adjusted EBITDA for Q4 rose 50% to $52.5 million, demonstrating improved operational scaling and efficiency.

UroGen reported a transformative fourth quarter marked by the initial commercial launch of ZUSDURI and steady growth for JELMYTO. The company successfully refinanced its debt to strengthen its balance sheet and is seeing accelerated physician adoption following the implementation of a permanent J Code for ZUSDURI in early 2026.

• ZUSDURI commercial launch is on-track with $15.8 million in net sales during its initial launch period in 2025.
• JELMYTO achieved $94 million in full-year sales, with underlying demand growing 7% year-over-year.

Vitesse Energy experienced a challenging fourth quarter with a net loss of $0.7 million, despite a significant year-over-year production increase driven by the Lucero acquisition. The company focused on maintaining its dividend and announced a new $35 million all-stock acquisition in the Powder River Basin to bolster 2026 production.

• Reported a Q4 net loss of $0.7 million and Adjusted Net Income of $0.2 million.
• Q4 production averaged 17,653 Boe per day, a slight 3% sequential decrease from Q3 2025.

LendingTree achieved record fourth-quarter revenue of $319.7 million, driven by strong performance in the Insurance segment. While GAAP net income was significantly bolstered by a $146.4 million tax benefit, the company saw a non-GAAP adjusted net loss for the quarter. Management highlighted market share gains in Insurance and a strengthened financial position with reduced net leverage.

• Consolidated revenue reached a Q4 record of $319.7 million, up 22% year-over-year.
• Insurance segment revenue grew 25% to $214.6 million, remaining the company's primary growth engine.

Kosmos Energy generated $294623000 in oil and gas revenue in Q4 2025 but reported a net loss of $377141000 primarily due to $177563000 in asset impairments and $151092000 in suspended well cost impairments. Production increased quarter-over-quarter, while free cash flow remained negative.

• Reported net loss of $377141000 impacted by impairments and exploration costs.
• Oil and gas revenue totaled $294623000 for the quarter.

Sturm Ruger achieved Q4 net sales of $151.1 million, a 3.6% increase year-over-year, driven by strong new product launches including the Glenfield rifle and Red Label III shotgun. However, GAAP diluted EPS fell to $0.21 from $0.62 in the prior year, while adjusted EPS stood at $0.26. For the full year, the company generated $54.3 million in cash from operations and returned $36.1 million to shareholders.

• Q4 net sales grew 3.6% to $151.1 million despite a challenging consumer environment.
• The company launched 65 new models in Q4, including three new platforms: Glenfield by Ruger, Red Label III, and the Harrier rifle.

ThredUp delivered a strong fourth quarter with revenue growing 18% year-over-year to $79.7 million and reaching a record 1.65 million active buyers. While the company reported a net loss, it achieved positive annual total cash flows for the first time in its history and maintained high gross margins near 80%.

• Quarterly revenue increased 18% year-over-year to $79.7 million.
• Active Buyers reached a record 1.65 million, a 30% increase over the previous year.

Crawford & Company faced a challenging fourth quarter with revenues decreasing 11% to $308.5 million, primarily due to a lack of severe storm activity in North America compared to the hurricane-impacted prior year. Despite a GAAP net loss of $7.2 million driven by $14.0 million in restructuring charges, the company achieved record annual revenues in its Broadspire and International segments and announced a new global operating structure to streamline execution in 2026.

• Revenues before reimbursements fell 11% in Q4 due to lower weather-related activity in North America Loss Adjusting and Platform Solutions.
• The company reported a Q4 net loss of $7.2 million, largely attributed to $14.0 million in pretax restructuring and other costs.

iHeartMedia reported a slight revenue increase of 0.8% in Q4 2025, driven by strong growth in the Digital Audio Group, particularly in podcasting. However, consolidated Adjusted EBITDA and operating income declined year-over-year, primarily due to lower political revenue compared to the 2024 presidential election year and increased operating expenses.

• Digital Audio Group revenue grew 14.1% year-over-year, with Podcast revenue specifically increasing by 24.5%.
• Multiplatform Group revenue declined 2.8% due to lower political advertising and broadcast spot revenue.

Cerus achieved record product revenue in Q4 2025, driven by strong demand in EMEA and U.S. IFC sales. The company narrowed its GAAP net loss and maintained positive non-GAAP adjusted EBITDA, while generating positive operating cash flow for the quarter.

• Product revenue grew 14% year-over-year to $57.8 million in Q4.
• U.S. INTERCEPT Fibrinogen Complex (IFC) sales increased to $4.2 million, up from $3.0 million in the prior year period.

Agora delivered Q4 2025 revenue growth of 10.7% year-over-year, driven by expansion in both the Agora and Shengwang segments. The company achieved GAAP net income of 4918000 and continued strong cash generation, supported by operating leverage and interest income.

• Total revenue increased 10.7% year-over-year to 38155000.
• Agora segment revenue grew 14.4% to 19900000, while Shengwang increased 5.7% to 18300000.

James River returned to profitability in the fourth quarter of 2025, reporting a significant improvement in its combined ratio to 94.1% and an underwriting profit of $8.6 million. The results were bolstered by a one-time tax benefit from redomiciling to Delaware and strong performance in the Excess and Surplus (E&S) segment, despite a strategic decline in gross written premiums as the company focuses on smaller, more profitable accounts.

• Achieved a consolidated combined ratio of 94.1% compared to 155.1% in the prior year quarter.
• The E&S segment reported an underwriting profit of $19.7 million, its best quarterly result since 2022.

For Q4 2025, StealthGas reported revenue of 39371480 and net income of 12775556, with EBITDA of 17339610. The company maintained strong profitability despite lower revenues and ended the quarter with 99077831 in cash and no long-term debt.

• Q4 2025 revenue was 39371480, down from 43467117 in Q4 2024.
• Net income for the quarter was 12775556 with basic EPS of 0.34.

Quanterix reported strong Q4 2025 revenue growth of 25% year-over-year, reaching $43.9 million, driven by product sales. Despite a decline in gross margins due to acquisition-related impacts, the company is progressing toward its goal of cash flow breakeven in 2026 following the integration of Akoya Biosciences.

• Q4 revenue grew 25% year-over-year to $43.9 million, exceeding internal expectations.
• Submitted 510(k) premarket notification to the FDA for a multi-analyte Alzheimer’s blood test in January 2026.

WhiteHorse Finance reported a decrease in net investment income for Q4 2025 compared to the prior year, primarily due to lower yields and a smaller portfolio size. Despite this, the company saw an increase in Net Asset Value (NAV) per share from the previous quarter and maintained active investment deployments while managing underperforming credits through restructuring.

• Net investment income for Q4 was $6.6 million, or $0.287 per share, down from $8.0 million in Q4 2024.
• Net Asset Value (NAV) per share increased to $11.68 from $11.41 at the end of Q3 2025.

BRC Inc. achieved Q4 revenue of $112.7 million, driven by growth in Wholesale and DTC channels, though gross margins were pressured by green coffee inflation and formulation-related impairments. The company successfully reduced debt and improved its capital structure during the fiscal year while setting a growth-oriented outlook for 2026.

• Net revenue increased 6.5% year-over-year to $112.7 million in Q4 2025.
• Wholesale revenue grew 8.4% due to distribution gains and improved velocity in packaged coffee.

OFS Capital reported a challenging fourth quarter with a net loss of $10.8 million, primarily driven by $12.8 million in net unrealized depreciation on investments. Net investment income also saw a slight decline due to interest rate cuts and a smaller performing portfolio, leading to a decrease in Net Asset Value per share to $9.19.

• Net investment income decreased to $0.20 per share from $0.22 in the previous quarter.
• Net Asset Value (NAV) per share dropped significantly to $9.19 from $10.17 as of September 30, 2025.